Abstract: Platinum-containing compounds for the treatment of disease, such as, for example, cancer, are provided herein. Specifically, platinum Pt(IV) complexes with a substituted 2,2?-bipyridine ring structure are provided, as are methods for using the complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: This disclosure provides fire retardant materials, including polymers that include at least one pyridinium salt moiety and at least one phosphine oxide moiety.

Abstract: This disclosure provides fire retardant materials, including polymers that include at least one pyridinium salt moiety and at least one phosphine oxide moiety.

Abstract: Platinum-containing compounds for the treatment of disease, such as, for example, cancer, are provided herein. Specifically, platinum Pt(IV) complexes with a substituted 2,2?-bipyridine ring structure are provided, as are methods for using the complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: This document provides fire retardant materials, including polymers that include pyridinium salt moieties, or a combination thereof, and phosphine oxide moieties. In some cases, fire retardant polymers provided herein have the following structure: where R1 and R6 are each selected consisting of N, wherein R2 and R7 are each negatively charged counterions, where R3, R4, R8, R9, R11, R13, R14, R15, and R16 are each H or a group including one or more carbon molecules, and where R5, R10, and R12 are each groups including one or more carbon molecules.

Abstract: This document provides fire retardant materials, including polymers that include pyridinium salt moieties, or a combination thereof, and phosphine oxide moieties. In some cases, fire retardant polymers provided herein have the following structure: where R1 and R6 are each selected consisting of N, wherein R2 and R7 are each negatively charged counterions, where R3, R4, R8, R9, R11, R13, R14, R15, and R16 are each H or a group including one or more carbon molecules, and where R5, R10, and R12 are each groups including one or more carbon molecules.

Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.

Abstract: A method of reducing the in vivo viability of cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells has steps of: a) identifying a prospective patient having cancer cells selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and melanoma cancer cells; and b) administering a cisplatin derivative to the prospective patient so that the cisplatin derivative will contact the cancer cells; wherein the cisplatin derivative is a 4,4?-bis[RO]-2,2?-bipyridine)PtCl2 where, R is selected from the group consisting of —(CH2)nCH3 where n=2, 3, 4 or 5, and —(CH2)n[O(CH2)m]yO(CH2)zCH3 where n=2, m=2, y=2, z=1. A novel synthetic process for the manufacture of these compounds (and their analogs) is also provided.